NGL Fine-Chem Limited is an integrated manufacturer of pharmaceutical APIs, primarily focused on veterinary APIs, plus human APIs, intermediates and a small finished-dosage portfolio, operating three state-of-the-art facilities in Tarapur and Navi Mumbai with WHO-GMP and other international accreditations and a large global customer base.

Q3FY26 financials show accelerating recovery with revenue from operations at ₹127.51 crore (up 43% YoY) and 9MFY26 revenue at ₹351.89 crore (up 28.7% YoY); EBITDA improved sharply to ₹22.31 crore in Q3 with a 17.5% margin, reflecting easing raw material costs and operational efficiencies that materially lifted profitability.

The company is reducing product concentration and expanding geographic reach: top-3 product share declined to 28% and top-10 products to 65% in Q3FY26, while regulatory filings (CEPs, ASMF approvals, VMF filings) indicate deliberate progress toward higher-value regulated markets and an ambition to increase revenue from controlled markets.

Operational differentiation includes ~95% in-house manufacturing, 75% production from zero-liquid-discharge facilities and strong backward integration, which together support cost competitiveness, consistent quality with no market rejection in 15 years, and the company’s stated goal of achieving asset turnover greater than two times from new investments.